Clinical trials: Urinary Complications
Complicated Urinary Tract Infection, Acute Pyelonephritis
A Study of Plazomicin Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP)
This was a multi-center, multi-national, double-blind, randomized, comparator-controlled study of plazomicin administered intravenously compared with levofloxacin, a standard approved intravenous therapy for complicated urinary…
- Trial name
- NCT01096849
- Testing
- levofloxacin, plazomicin
- Volunteers
- 145 people
- Sponsor
- Achaogen, Inc.
Urinary Incontinence, Stress
Autologous Cell Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery
To study the safety and potential efficacy of Autologous Muscle Derived Cells for Urinary Sphincter Repair (AMDC-USR) for the treatment of male stress urinary incontinence (SUI) for patients that have undergone prior prostate…
- Conditions
- Urinary Incontinence, Stress, Urination Disorders, Urologic Diseases
- Trial name
- NCT02291432
- Testing
- autologous muscle-derived cells (AMDC)
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Cook MyoSite
Urothelial Cancer, Bladder Cancer
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
This is a global, multicenter, randomized, open-label, Phase 2/3 study of Dato-DXd plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin in participants with la/mUC who progressed during or after EV plus…
- Trial name
- NCT07129993
- Testing
- Dato-DXd, Carboplatin, Cisplatin
- Where
- 100 sites in United States, Austria and 5 more
- Volunteers
- 630 people
- Sponsor
- Daiichi Sankyo
Respiratory Tract Infections, Urinary Tract Infections
Sepsis Prognosis and Diagnosis in the Emergency Department (SPEED)
This study aims to evaluate the diagnostic and prognostic performance of a novel mRNA diagnostic/prognostic classifier (interprets the expression of 29 host response mRNA biomarkers) from whole blood in adult patients presenting…
- Conditions
- Respiratory Tract Infections, Urinary Tract Infections, Intra-Abdominal Infections, Skin and Soft Tissue Infection
- Trial name
- NCT05639504
- Testing
- IMX-BVN-4 and IMX-SEV-4
- Sponsor
- Inflammatix
Solid Tumor, Colorectal Cancer
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or…
- Conditions
- Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer
- Trial name
- NCT03872947
- Testing
- TRK-950, Irinotecan, Leucovorin
- Where
- 14 sites in United States, France
- Volunteers
- 138 people
- Sponsor
- Toray Industries, Inc
Complicated Urinary Tract Infections
LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI)
The purpose of the study is to evaluate whether LYS228 can be developed for the treatment of complicated urinary tract infections
- Trial name
- NCT03377426
- Testing
- LYS228, Standard of care therapy
- Where
- 5 sites in United States, Denmark and 1 more
- Sponsor
- Novartis Pharmaceuticals
Overactive Bladder
A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.
1. Primary Objective: To evaluate the dose-response relationship of tarafenacin on efficacy. 2. Secondary Objectives: To compare 12 weeks' efficacy of different doses of tarafenacin to that of placebo in patients suffering from…
- Trial name
- NCT01458197
- Testing
- Tarafenacin 0.2 mg, Tarafenacin 0.4 mg
- Where
- South Korea
- Volunteers
- 235 people
- Sponsor
- Kwang Dong Pharmaceutical co., ltd.
Urinary Incontinence
A Study to Evaluate the Safety and Efficacy of OROS® Oxybutynin Chloride for the Treatment of Urge Urinary Incontinence
The purpose of this study is to is to evaluate the safety and efficacy of OROS® oxybutynin chloride in patients being treated for urge urinary incontinence.
- Trial name
- NCT00269724
- Testing
- OROS® oxybutynin
- Volunteers
- 250 people
- Sponsor
- Alza Corporation, DE, USA
Urinary Incontinence
Bi-Polar Radio-Frequency and Electrical Muscle Stimulation for Symptoms of Mixed Urinary Incontinence (MUI)
The objective of this trial is to evaluate the safety and efficacy of the combined FormaV and VTone Applicators for Symptoms of Mixed Urinary Incontinence.
- Trial name
- NCT05287490
- Testing
- FormaV and VTone
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- InMode MD Ltd.
Urinary Incontinence
An Evaluation of the PureWick™ Male External Catheter Versus an Established Comparator Overnight in the Home Setting for Incontinence in Adult Males
This post-market study will assess the performance of and user satisfaction with the PureWick™ Male External Catheter in a home setting.
- Trial name
- PUREST-M (NCT07282860)
- Testing
- PureWick System, UltraFlex Self-Adhering Male External Catheter
- Where
- 15 sites in United States
- Volunteers
- 120 people
- Sponsor
- C. R. Bard
Non-muscle Invasive Bladder Cancer
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
The purpose of this study is to learn how a new medicine called PF-08052667 works when used by itself or together with another medicine called Bacillus Calmette Guerin (BCG), and/or a medicine called sasanlimab.
- Trial name
- NCT07206225
- Testing
- PF-08052667, Sasanlimab, BCG
- Where
- 69 sites in United States, France and 4 more
- Volunteers
- 294 people
- Sponsor
- Pfizer
Bladder Cancer
Neoadjuvant Chemo (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder Cancer
The purpose of this study is to evaluate efficacy of gemcitabine and cisplatin combined with either radical cystectomy or radiotherapy in the treatment of bladder cancer.
- Trial name
- NCT00490880
- Testing
- gemcitabine, cisplatin, radical cystectomy
- Where
- Poland
- Volunteers
- 2 people
- Sponsor
- Eli Lilly and Company
Stress Urinary Incontinence
TVT Worldwide Registry
The objective of this observational study is to obtain long -term clinical and patient reported outcomes on the use of the GYNECARE family of TVT (Tension-Free Vaginal Tape) systems in women with stress urinary incontinence.
- Trial name
- NCT00453739
- Where
- 30 sites in United States, Australia and 7 more
- Volunteers
- 1,407 people
- Sponsor
- Ethicon, Inc.
Urinary Retention, Neurogenic Bladder
Connected Catheter- Safety and Effectiveness Study
The Connected Catheter is a fully internal, urethral indwelling urinary prosthesis designed for improved bladder management in males with urinary retention disorders requiring catheterization.
- Conditions
- Urinary Retention, Neurogenic Bladder, Urologic Diseases
- Trial name
- NCT03843073
- Testing
- Connected Urinary Catheter
- Where
- 9 sites in United States
- Volunteers
- 9 people
- Sponsor
- Spinal Singularity
Interstitial Cystitis, IC
Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC Patients
The investigators believe that this study is of importance of several aspects: 1. It evaluates a new mode of bladder instillation that may bypass the drawbacks of the current instillation mode. 2.
- Trial name
- NCT01997983
- Testing
- TC-3 Gel mixed with Botox (BTX)
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- UroGen Pharma Ltd.
Sexually Transmitted Diseases
Prospective Registry of Exposure to Gepotidacin (PREG)
The purpose of this study is to monitor pregnancies exposed to gepotidacin and to evaluate possible teratogenic effects or birthweight-lowering effects of this medication relative to the primary outcomes of major congenital…
- Trial name
- NCT07850141
- Testing
- None (Observational study)
- Volunteers
- 614 people
- Sponsor
- GlaxoSmithKline
Kidney Stone, Ureteral Stone
The Performance of the SOLTIVE Laser System for Laser Lithotripsy in Kidney or Ureteral Stones
The purpose of this study is to collect real-world evidence on the performance of the SOLTIVE™ Premium SuperPulsed Laser System for laser lithotripsy in ureteroscopy, percutaneous nephrolithotomy (PCNL) and mini PCNL for kidney…
- Trial name
- NCT04556201
- Testing
- SOLTIVE™ Premium SuperPulsed Laser Fiber System
- Where
- 7 sites in United States, Denmark and 1 more
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Olympus Corporation of the Americas
Urinary Tract Infections
Drug Interaction Assessment of GSK3882347 in Healthy Participants Aged 18 to 65 Years
The objective of this study is to determine the magnitude and clinical relevance of a potential drug-drug interaction of GSK3882347 with midazolam (MDZ) in healthy participants.
- Trial name
- NCT05760261
- Testing
- Midazolam, GSK3882347
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Melanoma, Non-Small Cell Lung Cancer
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in…
- Conditions
- Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Colorectal Cancer
- Trial name
- NCT03289962
- Testing
- Autogene cevumeran, Atezolizumab
- Where
- 33 sites in United States, Belgium and 6 more
- Volunteers
- 273 people
- Sponsor
- Genentech, Inc.
Urinary Retention
Assessment of CymActive™ Catheter Technology for UrinAry ReTention and AcceptancE (The ACCTUATE Study)
The ACCTUATE study: Assessment of CymActive™ Catheter Technology for UrinAry reTention and acceptancE study will evaluate a novel catheter design that addresses the specific needs of male long term catheter users living in the…
- Trial name
- ACCTUATE (NCT05848037)
- Testing
- cymactive™ catheter device (CCD), Foley-type catheter device
- Where
- 5 sites in United Kingdom
- Volunteers
- 6 people
- Sponsor
- Ingenion Medical Limited